Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia.

Kamen A. Tsvetanov,[*,1,2] Stefano Gazzina,[*,1,3] Simon P. Jones,[1] John van Swieten,[3] Barbara Borroni,[4] Raquel Sanchez-Valle,[5] Fermin Moreno,[6, 7] Robert Laforce Jr,[8] Caroline Graff,[9] Matthis Synofzik,[10,11] Daniela Galimberti,[12,13] Mario Masellis,[14] Maria Carmela Tartaglia,[15] Elizabeth Finger,[16] Rik Vandenberghe,[17,18] Alexandre de Mendonça,[19] Fabrizio Tagliavini,[20] Isabel Santana,[21,22,23] Simon Ducharme,[24,25] Chris Butler,[26] Alex Gerhard,[27] Adrian Danek,[28] Johannes Levin,[28] Markus Otto,[29] Giovanni Frisoni,[30,31] Roberta Ghidoni,[32] Sandro Sorbi,[33,34] Jonathan D. Rohrer,[35] and James B. Rowe,[1,2,36] on behalf of the Genetic FTD Initiative, GENFI.[#]

[*]*Joint first authorship*

1 Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK

2 Cambridge Centre for Ageing and Neuroscience (Cam-CAN), University of Cambridge and MRC Cognition and Brain Sciences Unit, Cambridge, UK

3 Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands

4 Centre for Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy

5 Alzheimer's disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Institut d'Investigacións Biomèdiques August Pi I Sunyer, University of Barcelona, Barcelona, Spain

6 Cognitive Disorders Unit, Department of Neurology, Hospital Universitario Donostia, San Sebastian, Gipuzkoa, Spain

7 Neuroscience Area, Biodonostia Health Research Insitute, San Sebastian, Gipuzkoa, Spain

8 Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, CHU de Québec, and Faculté de Médecine, Université Laval, Québec, Canada

9 Karolinska Institutet, Department NVS, Center for Alzheimer Research, Division of Neurogenetics, Stockholm, Sweden

10 Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research & Center of Neurology, University of Tübingen, Germany

11 German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany

29 *12 University of Milan, Centro Dino Ferrari, Milan, Italy*

30 *13 Fondazione IRCSS Ca' Granda, Ospedale Maggiore Policlinico, Neurodegenerative Diseases Unit, Milan, Italy*

31 *14 LC Campbell Cognitive Neurology Research Unit, Sunnybrook Research Institute, Toronto, Ontario, Canada*

32 *15 Toronto Western Hospital, Tanz Centre for Research in Neurodegenerative Disease, Toronto, Ontario, Canada*

33 *16 Department of Clinical Neurological Sciences, University of Western Ontario, London, ON, Canada*

34 *17 Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium*

35 *18 Neurology Service, University Hospitals Leuven, Belgium, Laboratory for Neurobiology, VIB-KU*

36 *19 Laboratory of Neurosciences, Institute of Molecular Medicine, Faculty of Medicine, University of Lisbon, Lisbon,*
37 *Portugal*

38 *20 Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta, Milan, Italy*

39 *21 Neurology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal*

40 *22 Faculty of Medicine, University of Coimbra, Coimbra, Portugal*

41 *23 Centre of Neurosciences and Cell biology, Universidade de Coimbra, Coimbra, Portugal*

42 *24 Department of Psychiatry, McGill University Health Centre, McGill University, Montreal, Canada*

43 *25 McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Canada*

44 *26 Nuffield Department of Clinical Neurosciences, Medical Sciences Division, University of Oxford, Oxford, UK*

45 *27 Faculty of Medical and Human Sciences, Institute of Brain, Behaviour and Mental Health, The University of Manchester,*
46 *Withington, Manchester, UK*

47 *28 Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität, Munich, German Center for Neurodegenerative*
48 *Diseases (DZNE), Munich, Germany*

49 *29 Department of Neurology, University Hospital Ulm, Ulm, Germany*

50 *30 Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia,*
51 *Italy*

52 *31 Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva,*
53 *Geneva, Switzerland*

54 *32 Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy*

33 Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy

34 Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) "Don Gnocchi", Florence, Italy

35 Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK

36 Medical Research Council Cognition and Brain Sciences Unit, Cambridge, UK

 # See Appendix for a list of GENFI consortium members.

Correspondence to:

Kamen A. Tsvetanov

e-mail: kat35@cam.ac.uk

Keywords (up to five): frontotemporal dementia (FTD), presymptomatic, functional magnetic resonance imaging (*f*MRI), network connectivity.

Abstract

INTRODUCTION: The presymptomatic phase of neurodegenerative disease can last many years, with sustained cognitive function despite progressive atrophy. We investigate this phenomenon in familial Frontotemporal dementia (FTD).

METHODS: We studied 121 presymptomatic FTD mutation carriers and 134 family members without mutations, using multivariate data-driven approach to link cognitive performance with both structural and functional magnetic resonance imaging. Atrophy and brain network connectivity were compared between groups, in relation to the time from expected symptom onset.

RESULTS: There were group differences in brain structure and function, in the absence of differences in cognitive performance. Specifically, we identified behaviourally-relevant structural and functional network differences. Structure-function relationships were similar in both groups, but coupling between functional connectivity and cognition was stronger for carriers than for non-carriers, and increased with proximity to the expected onset of disease.

DISCUSSION: Our findings suggest that maintenance of functional network connectivity enables carriers to maintain cognitive performance.

1. Introduction

Across the adult healthy lifespan, the structural and functional properties of brain networks are coupled, and both are predictive of cognitive ability [1,2]. The connections between structure, function and performance have been influential in developing current models of ageing and neurodegeneration [3–5]. However, this work contrasts with the emerging evidence of neuropathological and structural changes many years before the onset of symptoms of Alzheimer's disease and frontotemporal dementia (FTD) [6–8]. Genetic FTD with highly-penetrant gene mutations provides the opportunity to examine the precursors of symptomatic disease. Three main genes account for 10-20% of FTD cases: chromosome 9 open reading frame 72 (*C9orf72*), granulin (*GRN*) and microtubule-associated protein tau (*MAPT*). These genes vary in their phenotypic expression and in the age of onset [9]. Despite pleiotropy [10], environmental and secondary genetic moderation [11,12] all three mutations cause significant structural brain changes in key regions over a decade before the expected age of disease onset [7,13], confirmed by longitudinal studies [14,15].

The divergence between early structural change and late cognitive decline begs the question: how do presymptomatic gene carriers stay so well in the face of progressive atrophy? We propose that the answer lies in the maintenance of network dynamics and functional organisation [16]. Across the lifespan, functional brain network connectivity predicts cognitive status [17], and this connectivity-cognition relationship becomes stronger with age [18,19].

Our overarching hypothesis is that for those at genetic risk of dementia, the maintenance of network connectivity prevents the manifestation of symptoms despite progressive structural changes. A challenge is that neither the anatomical and functional substrates of cognition nor the targets of neurodegenerative disease are mediated by single brain regions: they are distributed across multi-level and interactive networks. We therefore used a multivariate data-driven approach to identify differences in the multidimensional brain-behaviour relationship between presymptomatic carriers and non-carriers of mutations in FTD genes. We identified key brain networks [20] from a large independent population-based age-matched dataset [21].

We tested three key hypotheses: (i) presymptomatic carriers differ from non-carriers in brain structure and brain function, but not in cognitive function, (ii) brain structure and function correlate with performance in

both groups, but functional network indices are stronger predictors of cognition in carriers, and (iii) the dependence on network integrity for maintaining cognitive functioning increases as carriers approach the onset of symptoms.

2. Methods

2.1. Participants

Thirteen research sites across Europe and Canada recruited participants as part of an international multicentre partnership, the Genetic Frontotemporal Initiative (GENFI). 313 participants had usable structural and resting state functional magnetic resonance imaging data (MRI) [7,13]. The study was approved by the institutional review boards for each site, and participants providing written informed consent. Five participants were excluded due to excessive head motion (see below), resulting in 308 datasets for further analysis.

Participants were genotyped based on whether they carried a pathogenic mutation in *MAPT, GRN* and *C9orf72*. In this study, we focus on non-carriers (NC, N=134) and presymptomatic carriers (PSC, N=121), i.e. gene carriers with normal cognitive function based on a neurocognitive assessment (see below). Participants and site investigators were blinded to the research genotyping, although a minority of participants had undergone predictive testing outwith the GENFI study. See Table 1 for demographic information of both groups. In keeping with other GENFI reports, the years to expected onset (EYO) were calculated as the difference between age at assessment and mean age at onset within the family [7].

2.2. Neurocognitive assessment

Each participant completed a standard clinical assessment consisting of medical history, family history, functional status and physical examination, in complement with collateral history from a family member or a close friend. In the current study 13 behavioural measures of cognitive function were correlated with neuroimaging measures. These included the Uniform Data Set [22]: the Logical Memory subtest of the Wechsler Memory Scale-Revised with Immediate and Delayed Recall scores, Digit Span forwards and backwards from the Wechsler Memory Scale-Revised, a Digit Symbol Task, Parts A and B of the Trail Making Test, the short version of the Boston Naming Test, and Category Fluency (animals). Additional tests included three subscores of the Letter Fluency and Wechsler Abbreviated Scale of Intelligence Block Design task, and the Mini-Mental State Examination. Latency measures for the Trail Making Test were inverted so that higher values across all tests reflect better performance.

141

142 ## 2.3. Neuroimaging assessment

143 Figure 1 provides a schematic representation of imaging data processing pipeline and the analysis strategy
144 for linking brain-behaviour data. MRI data were acquired using 3T scanners and 1.5T where no 3T scanning
145 was available from various vendors, with optimised scanning protocols to maximise synchronisation across
146 scanners and sites [7,13]. A 3D-structural MRI was acquired on each participant using T1-weighted
147 Magnetic Prepared Rapid Gradient Echo sequence. The co-registered T1 images were segmented to extract
148 probabilistic maps of 6 tissue classes: grey matter (GM), white matter (WM), cerebrospinal fluid (CSF),
149 bone, soft tissue, and residual noise. The native-space GM and WM images were submitted to
150 diffeomorphic registration to create equally represented gene-group template images [DARTEL; 23]. The
151 templates for all tissue types were normalised to the Montreal Neurological Institute template using a 12-
152 parameter affine transformation. The normalised images were smoothed using an 8-mm Gaussian kernel.

153 For resting state fMRI measurements, Echo-Planar Imaging data were acquired with at least six minutes of
154 scanning. The imaging data were analysed using Automatic Analysis [AA 4.0; ,24] pipelines and modules
155 which called relevant functions from SPM12 [25]. To quantify the total motion for each participant, the root
156 mean square volume-to-volume displacement was computed using the approach of Jenkinson et al [26].
157 Participants with 3.5 or more standard deviations above the group mean motion displacement were
158 excluded from further analysis (N = 5). To further ensure that potential group bias in head motion did not
159 affect later analysis of connectivity, we took three further steps: i) fMRI data was further postprocessed
160 using whole-brain Independent Component Analysis (ICA) of single subject time-series denoising, with
161 noise components selected and removed automatically using *a priori* heuristics using the ICA-based
162 algorithm [27], ii) postprocessing of network node time-series (see below) and iii) a subject-specific
163 estimate of head movement for each participant [26] included as a covariate in group-level analysis [28].

164 ## 2.4. Network definition

165 The location of the key cortical regions in each network was identified by spatial-ICA in an independent
166 dataset of 298 age-matched healthy individuals from a large population-based cohort [21]. Full details
167 about preprocessing and node definition are described previously [29]. Four networks commonly affected
168 by neurodegenerative diseases including FTD [20] were identified by spatially matching to pre-existing
169 templates [30]. The node time-series were defined as the first principal component resulting from the

singular value decomposition of voxels in an 8-mm radius sphere, which was centred on the peak voxel for each node [18]. Visual representation of the spatial distribution of the nodes is shown in Figure 2.

We aimed to further reduce the effects of noise confounds on functional connectivity effects of node time-series using general linear model (GLM) [28]. This model included linear trends, expansions of realignment parameters, as well as average signal in WM and CSF, including their derivative and quadratic regressors from the time-courses of each node. The WM and CSF signals were created by using the average signal across all voxels with corresponding tissue probability larger than 0.7 in associated tissue probability maps available in SPM12. A band-pass filter (0.0078-0.1 Hz) was implemented by including a discrete cosine transform set in the GLM. Finally, the functional connectivity (FC) between each pair of nodes was computed using Pearson's correlation on postprocessed time-series.

2.5. Statistical analysis

2.5.1. Group differences in brain structure, function and cognition

To assess the group-differences in neuroimaging and behavioural dataset we used multiple linear regression with a well-conditioned shrinkage regularization [31,32] and 10-Fold Cross–Validation [33]. In the analysis of brain structure we used as independent variables the mean grey matter volume (GMV) of 246 brain nodes [34]. In the analysis of brain function, we used the functional connectivity between 15 nodes, which were part of the four large-scale functional networks described above. In the analysis of cognitive function, the independent variables comprised the performance measures on the 13 neuropsychological tests performed outside of the scanner. In all three analyses the dependent variable was the genetic status (PSC vs NC) including age as a covariate of no interest. In addition, in the analysis of neuroimaging data we included scanner site and head motion as additional covariates of no interest.

2.5.2. Brain-behaviour relationships

For the brain-behaviour analysis, we adopted a two-level procedure. In the first-level analysis, we assessed the multidimensional brain-behaviour relationships using partial least squares [35]. This analysis described the linear relationships between the two multivariate datasets, namely neuroimaging (either GMV or FC) and behavioural performance, by providing pairs of latent variables (Brain-LVs and Cognition-LVs) as linear combinations of the original variables which are optimised to maximise their covariance. Namely, dataset 1 consisted of a brain feature set, which could be either grey matter volume (GMV dataset) or functional

connectivity strength between pairs of regions for each individual (FC dataset). Dataset 2 included the performance measures on the 13 tests (i.e. Cognition dataset), as considered in the multiple linear regression analysis of group differences in cognition. Covariates of no interest included head motion, scanner site, gender and handedness.

Next, we tested whether the identified behaviourally-relevant LVs of brain structure and function were differentially expressed by NC and PSC as a function of expected years to onset. To this end, we performed a second-level analysis using multiple linear regression with robust fitting algorithm as implemented in matlab's function "fitlm.m". Independent variables included subjects' brain scores from first level PLS (either Structure-LV or Function-LV subject scores), group information, expected years to onset and their interaction terms (e.g. brain scores x group, brain scores x years to expected onset, etc.). The dependent variable was subjects' cognitive scores from the first level analysis in the corresponding PLS (Cognition-LV). Covariates of no interest included gender, handedness, head movement and education (Figure 1).

3. Results

3.1. Group differences in neuroimaging and cognitive data

Brain structure

The multiple linear regression model testing for overall group differences in grey matter volume between PSC and NC was significant (r=.14, p=.025), reflecting expected presymptomatic differences in brain-wide atrophy. The frontal, parietal and subcortical regions had most atrophy in PSC (Figure 3). As expected, the group difference in grey matter volume of these regions increased as EYO decreased, see Supplementary Materials.

Brain Function

The multiple linear regression model testing for overall group differences in functional connectivity between PSC and NC was marginally significant (r=.12, p=.049). The pattern of connectivity indicated mainly increased connectivity between SN-DMN and SN-FPN in presymptomatic carriers, coupled with decreased connectivity within the networks and DMN-FPN connectivity (Figure 3).

Cognitive Function

We did not identify group differences in cognition and behaviour (r=.002, p=.807), confirming the impression of "healthy" status among presymptomatic carriers. However, in the next section, we consider

227 the relationships between structure, function and cognition that underlie this maintenance of cognitive
228 function.

229 3.2. Brain-behaviour relationships

230 *Structure-cognition*

231 Partial least squares analysis of grey matter volume and cognition identified one significant pair of latent
232 variables (r = .40, p = .009). This volumetric latent variable expressed negative loadings in frontal (superior
233 frontal gyrus, precentral gyrus, paracentral lobule), parietal (postcentral gyrus, precuneus, superior and
234 inferior parietal lobule) and occipital (lateral and medial occipital cortex) regions and positive loadings in
235 parahippocampal and hippocampal regions (Figure 4). The Cognition-LV profile expressed positively a large
236 array of cognitive tests, with strongest values on delayed memory, Trail Making, Digit Symbol, Boston
237 Naming and Fluency tests. The positive correlation between volumetric and cognitive LV's confirms the
238 expected relationship across the cohort as a whole, between cortical grey matter volume and both
239 executive, language and mnemonic function (Figure 4).

240 To understand the structure-cognition relationship in each group and in relation to the expected
241 years of onset, we performed a second-level moderation analysis using a regression model: we entered
242 Cognition-LV subject scores as dependent variable, and grey matter volume LV subject scores, genetic
243 status (i.e. carrier or non-carrier), expected years to onset and their interactions as independent variables
244 in addition to covariates of no interest. The results indicated that the relationship between grey matter
245 volume and cognition could not be explained by genetic status, expected years to onset or their interactions
246 with grey matter volume LV subject scores. There was no evidence for genetic status- and onset-dependent
247 differences (over and above ageing and other covariates) in the associations between grey matter volume
248 and cognition in this analysis (Figure 4).

249 *Connectivity-Cognition*

250 PLS analysis of functional connectivity and cognition also identified one significant pair of LVs (Function-LV
251 and Cognition-LV, r=.32, p=.020), see Figure 5. This Function-LV reflected weak between-network
252 connectivity, coupled with strong within-network connectivity. This pattern indicates the segregation or
253 modularity of large-scale brain networks. The Cognition-LV expressed all tests, with positive loading values
254 indicating that higher performance on a wide range of cognitive tests is associated with stronger functional
255 network segregation. Cognitive deficits were associated with loss of segregation, with increased between-
256 network connectivity and decreased within-network connectivity.

To further test whether the observed behaviourally-relevant pattern of connectivity is differentially expressed between genetic status groups and expected years of onset, we constructed a second-level regression model with robust error estimates by including Function-LV subject scores, genetic status, expected years of onset and their interaction terms as independent variables and Cognition-LV as dependent variable in addition to covariates of no interest (Figure 5).

We found evidence for significant interaction between expected years of onset and Function-LV ($r=.21$, $p<.001$) and between group and Function-LV ($r=.15$, $p=.003$) explaining unique variance in Cognition-LV. We used the Dawson and Richter approach [36] to test formally for differences in the relationship (i.e. simple slopes) between Function-LV and Cognition-LV for PSC and NC. The relationship between Function-LV and Cognition-LV was stronger for PSC relative to NC ($r=.15$, $p=.003$), indicating the increasing importance of functional connectivity between the large-scale networks for PSC participants to maintain performance (Figure 5).

For ease of interpretation and illustration, we also computed the correlation between Cognition-LV and Function-LV for high and low levels of expected years to onset (EYO) within each group separately, where the levels were taken to be 1 standard deviation above and below the mean values of EYO. The two EYO subgroups were labelled “near” and “far”, with “near” for EYO values close to zero (i.e. participant’s age is “near” the age at which disease symptoms were demonstrated in the family), and “far” for EYO being a largely negative value (i.e. participant’s age is “far” from the age at which disease symptoms were demonstrated in the family). The analysis indicated that as the EYO decreases (i.e. participant’s age is reaching the years of onset of symptoms) the relationship between functional connectivity and performance becomes stronger (moderation effects: $r=.14$, $p=.021$ and $r=.28$, $p<.001$ for NC and PSC, respectively). Interestingly this relationship was stronger in each EYO subgroup for PSC relative to NC (PSC-Near vs NC-Near: $r=.28$, $p<.001$; PSC-Far vs NC-Far: $r=.22$, $p=.001$). These findings indicate that the relationship between FC and cognition is stronger in PSC relative to NC, and that this relationship increases as a function of EYO.

4. Discussion

In the present study, we confirmed previous findings of group differences in brain structure and function, in the absence of differences in cognitive performance between non-carriers and presymptomatic carriers

286 of FTD-related genetic mutations. But, while the relationship between structure and cognition was similar
287 in both groups, the coupling between function and cognition was stronger for presymptomatic carriers,
288 and increased as they approached the expected onset of disease.

289 These results suggest that people can maintain good cognitive abilities and successful day-to-day
290 functioning despite significant neuronal loss and atrophy. This disjunction between structure and function
291 is a feature of healthy ageing, but we have shown that it also characterises presymptomatic FTD, over and
292 above the age effects in their other family members, despite widespread progressive atrophy. The
293 multivariate approach reveals two key findings: (i) presymptomatic carriers express stronger between-
294 network and weaker within-network functional connectivity than age-matched non-carriers, and (ii) as
295 carriers approach their estimated age of symptom onset, and atrophy becomes evident, the maintenance
296 of good cognition is increasingly associated with sustaining balance of within- and between-network
297 integration.

298 This balance of within- and between-network connectivity is characteristic of segregated and specialized
299 network organization of brain systems. Such functional segregation varies with physiological ageing
300 [17,18,37], with cognitive function [18] and in individuals at risk for Alzheimer's disease [38]. Graph-
301 theoretic quantification of network organisation confirms the relevance of modularity and efficiency to
302 function in FTD [16]. Conversely, the loss of neural systems' modularity mirrors the loss of functional
303 specialization with age [39] and dementia [38]. Here, we show the significance of the maintenance of this
304 functional network organisation, with a progressively stronger correlation with cognitive performance as
305 seemingly healthy adults approach the age of expected onset of FTD.

306 The uncoupling of brain function from brain structure indicates that there may be independent and
307 synergistic effects of multiple factors leading to cognitive preservation. This is consistent with a previous
308 work in healthy ageing where brain activity and connectivity provide independent and synergistic
309 predictions of performance across the lifespan [19]. Therefore, future studies need to consider the
310 independent and synergistic effects of many possible biomarkers, based on MRI, computed tomography,
311 positron-emission tomography, CSF, blood and brain histopathology. For example, functional network
312 impairment may be related to tau expression and tau pathology, amyloid load, or neurotransmitter deficits
313 in neurodegenerative diseases, independent of atrophy [29,40–42]. Importantly, studies need to recognise
314 the rich multivariate nature of cognition and of neuroimaging in order to improve stratification procedures,
315 e.g. based on integrative approaches that explain individual differences in cognitive impairment [29,43].

316 We also recognise the difficulty to determine a unique contribution of each factor (e.g. brain structure and
317 brain function), given the increasing interaction between factors in advanced stages of disease [44]. This is
318 further complicated by these alterations becoming irreversible with progression of neurodegeneration
319 [45]. This suggests that the critical interplay between multiple factors (including brain structure and
320 function) may be better studied in the asymptomatic and preclinical stages as well as across the healthy
321 lifespan, which could still be modifiable and their influences are likely to be more separable.

322 Our findings agree with the model of compensation in the presymptomatic and early phases of
323 Huntington's disease, where network coupling predicted better cognitive performance [46]. In a recent
324 longitudinal study a non-linear concave-down pattern of both brain activity and behaviour was present,
325 despite a linear decline in brain volume over time, [47]. Similar effects have been observed also in healthy
326 ageing and amnestic mild cognitive impairment, where greater connectivity with the default-mode network
327 and weaker connectivity between default-mode network and dorsal-attention network was associated with
328 higher cognitive status in both groups [48]. Network integrity may also play a role in compensatory
329 mechanisms in non-cognitive symptoms, such as motor impairment in Parkinson's disease [49].
330 Accordingly, increased network efficiency and connectivity has been shown in prodromal phases, followed
331 by decreased local connectivity in symptomatic phases, suggesting the emergence and dissipation of neural
332 compensation [50].

333 The current study has several limitations. First, despite the large sample of subjects included, we did not
334 analyse each gene separately, as it may have resulted in too small and unbalanced samples, lowering
335 statistical power and robustness. Moreover, genetic FTD is also characterised by multiple mutations within
336 these genes and pleiotropy of clinical phenotypes even for the same mutation [10]. Pleiotropy in terms of
337 clinical phenotype is avoided by the study of presymptomatic carriers, but we cannot rule out pleiotropy
338 of intermediate phenotypes expressed as say neural network diversity. Furthermore, clinical heterogeneity
339 is modified by environmental factors such as education [which may be a surrogate of cognitive reserve, 51],
340 in FTD as in other dementias [12]. Genetic modifiers such as TMEM106B [52], APOE [53], have also been
341 identified. Further work, with larger cohorts, will be able to test the potential effect of these moderators
342 on the relationships between brain structure, functional networks and cognition. Future studies will benefit
343 from using brain measures that reflect differences in neural connectivity directly from neurophysiology or
344 separation of neurovascular from neuronal contributors to BOLD fMRI variance [18,54], which can
345 confound the effects of age, drug or disease [55].

346 The current study is cross-sectional. Therefore, we cannot infer longitudinal progression within subjects as
347 the unambiguous cause of the effects we observe in relation to expected years of onset. Accumulating
348 evidence suggests that network integrity serves to maintain performance with either physiological ageing
349 or pathological conditions. However, longitudinal mediation studies and pharmacological or electroceutical
350 interventions would be needed to prove its causal role in cognitive preservation. Finally, our findings are
351 limited to autosomal dominant FTD, which represents a minority of FTD: generalisation to sporadic forms
352 of disease would be speculative.

353 In conclusion, we used a multivariate data-driven approach to demonstrate that brain functional integrity
354 can enable presymptomatic carriers to maintain cognitive performance in the presence of progressive brain
355 atrophy for years before the onset of symptoms. The approach and the findings have implications for the
356 design of presymptomatic disease-modifying therapy trials and the study of unique and synergistic effects
357 of risk factors and biomarkers in health and disease, which are otherwise increasingly interacting and
358 irreversible with progression of neurodegeneration.

359

360

361 # 5. References

362

363 [1] Persson J, Nyberg L, Lind J, Larsson A, Nilsson LG, Ingvar M, et al. Structure-function correlates of
364 cognitive decline in aging. CerebCortex 2006;16:907–15.

365 [2] Geerligs L, Cam-CAN, Henson RN. Functional connectivity and structural covariance between
366 regions of interest can be measured more accurately using multivariate distance correlation.
367 Neuroimage 2016;135:16–31. doi:10.1016/j.neuroimage.2016.04.047.

368 [3] Cope TE, Rittman T, Borchert RJ, Jones PS, Vatansever D, Allinson K, et al. Tau burden and the
369 functional connectome in Alzheimer's disease and progressive supranuclear palsy. Brain
370 2018;141:550–67. doi:10.1093/brain/awx347.

371 [4] Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-
372 scale human brain networks. Neuron 2009;62:42–52. doi:10.1016/j.neuron.2009.03.024.

373 [5] Raj A, Kuceyeski A, Weiner M. A network diffusion model of disease progression in dementia.
374 Neuron 2012;73:1204–15. doi:10.1016/j.neuron.2011.12.040.

375 [6] Kinnunen KM, Cash DM, Poole T, Frost C, Benzinger TLS, Ahsan RL, et al. Presymptomatic atrophy
376 in autosomal dominant Alzheimer's disease: A serial magnetic resonance imaging study.
377 Alzheimer's Dement 2018;14:43–53. doi:10.1016/j.jalz.2017.06.2268.

378 [7] Rohrer JD, Nicholas JM, Cash DM, van Swieten J, Dopper E, Jiskoot L, et al. Presymptomatic
379 cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic
380 Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurol
381 2015;14:253–62. doi:10.1016/S1474-4422(14)70324-2.

382 [8] Vatsavayai SC, Yoon SJ, Gardner RC, Gendron TF, Vargas JNS, Trujillo A, et al. Timing and
383 significance of pathological features in *C9orf72* expansion-associated frontotemporal dementia.
384 Brain 2016;139:3202–16. doi:10.1093/brain/aww250.

385 [9] Deleon J, Miller BL. Frontotemporal dementia, 2018, p. 409–30. doi:10.1016/B978-0-444-64076-
386 5.00027-2.

387 [10] Snowden JS, Adams J, Harris J, Thompson JC, Rollinson S, Richardson A, et al. Distinct clinical and
388 pathological phenotypes in frontotemporal dementia associated with MAPT, PGRN and C9orf72
389 mutations. Amyotroph Lateral Scler Front Degener 2015;16:497–505.
390 doi:10.3109/21678421.2015.1074700.

391 [11] Murphy NA, Arthur KC, Tienari PJ, Houlden H, Chiò A, Traynor BJ. Age-related penetrance of the
392 C9orf72 repeat expansion. Sci Rep 2017;7:2116. doi:10.1038/s41598-017-02364-1.

393 [12] Premi E, Grassi M, Van Swieten J, Galimberti D, Graff C, Masellis M, et al. Cognitive reserve and
394 TMEM106B genotype modulate brain damage in presymptomatic frontotemporal dementia: a
395 GENFI study. Brain 2017;140:1784–91. doi:10.1093/brain/awx103.

396 [13] Cash DM, Bocchetta M, Thomas DL, Dick KM, van Swieten JC, Borroni B, et al. Patterns of gray
397 matter atrophy in genetic frontotemporal dementia: results from the GENFI study. Neurobiol Aging
398 2018;62:191–6. doi:10.1016/j.neurobiolaging.2017.10.008.

399 [14] Olm CA, McMillan CT, Irwin DJ, Van Deerlin VM, Cook PA, Gee JC, et al. Longitudinal structural gray
400 matter and white matter MRI changes in presymptomatic progranulin mutation carriers.
401 NeuroImage Clin 2018;19:497–506. doi:10.1016/J.NICL.2018.05.017.

402 [15] Floeter MK, Danielian LE, Braun LE, Wu T. Longitudinal diffusion imaging across the *C9orf72* clinical
403 spectrum. J Neurol Neurosurg Psychiatry 2018;89:53–60. doi:10.1136/jnnp-2017-316799.

404 [16] Rittman DT, Borchert MR, Jones MS, van Swieten J, Borroni B, Galimberti D, et al. Functional
405 network resilience to pathology in presymptomatic genetic frontotemporal dementia. Neurobiol
406 Aging 2019;77:169–77. doi:10.1016/J.NEUROBIOLAGING.2018.12.009.

407 [17] Chan MY, Park DC, Savalia NK, Petersen SE, Wig GS. Decreased segregation of brain systems across
408 the healthy adult lifespan. Proc Natl Acad Sci 2014;111:4997–5006.
409 doi:10.1073/pnas.1415122111.

410 [18] Tsvetanov KA, Henson RNA, Tyler LK, Razi A, Geerligs L, Ham TE, et al. Extrinsic and intrinsic brain
411 network connectivity maintains cognition across the lifespan despite accelerated decay of regional
412 brain activation. J Neurosci 2016;36:3115–26. doi:10.1523/JNEUROSCI.2733-15.2016.

413 [19] Tsvetanov KA, Ye Z, Hughes L, Samu D, Treder MS, Wolpe N, et al. Activity and connectivity
414 differences underlying inhibitory control across the adult lifespan. J Neurosci 2018;38:7887–900.

415 doi:10.1523/JNEUROSCI.2919-17.2018.

416 [20] Chhatwal JP, Schultz AP, Johnson KA, Hedden T, Jaimes S, Benzinger TLS, et al. Preferential
417 degradation of cognitive networks differentiates Alzheimer's disease from ageing. Brain
418 2018;141:1486–500. doi:10.1093/brain/awy053.

419 [21] Shafto MA, Tyler LK, Dixon M, Taylor JR, Rowe JB, Cusack R, et al. The Cambridge Centre for Ageing
420 and Neuroscience (Cam-CAN) study protocol: a cross-sectional, lifespan, multidisciplinary
421 examination of healthy cognitive ageing. BMC Neurol 2014;14:204. doi:10.1186/s12883-014-0204-
422 1.

423 [22] Morris JC, Weintraub S, Chui HC, Cummings J, DeCarli C, Ferris S, et al. The Uniform Data Set (UDS):
424 Clinical and Cognitive Variables and Descriptive Data From Alzheimer Disease Centers. Alzheimer
425 Dis Assoc Disord 2006;20:210–6. doi:10.1097/01.wad.0000213865.09806.92.

426 [23] Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage 2007;38:95–113.
427 doi:10.1016/j.neuroimage.2007.07.007.

428 [24] Cusack R, Vicente-Grabovetsky A, Mitchell DJ, Wild CJ, Auer T, Linke AC, et al. Automatic analysis
429 (aa): efficient neuroimaging workflows and parallel processing using Matlab and XML. Front
430 Neuroinform 2014;8:90. doi:10.3389/fninf.2014.00090.

431 [25] Friston KJ, Ashburner J, Kiebel S, Nichols T, Penny WD. Statistical parametric mapping : the analysis
432 of funtional brain images. Elsevier Academic Press; 2007.

433 [26] Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the robust and accurate
434 linear registration and motion correction of brain images. Neuroimage 2002;17:825–41.

435 [27] Pruim RHR, Mennes M, Buitelaar JK, Beckmann CF. Evaluation of ICA-AROMA and alternative
436 strategies for motion artifact removal in resting state fMRI. Neuroimage 2015;112:278–87.
437 doi:10.1016/j.neuroimage.2015.02.063.

438 [28] Geerligs L, Tsvetanov KA, Cam-Can, Henson RN. Challenges in measuring individual differences in
439 functional connectivity using fMRI: The case of healthy aging. Hum Brain Mapp 2017.
440 doi:10.1002/hbm.23653.

441 [29] Passamonti L, Tsvetanov KA, Jones PS, Bevan-Jones WR, Arnold R, Borchert RJ, et al.

442 Neuroinflammation and functional connectivity in Alzheimer's disease: interactive influences on
443 cognitive performance. BioRxiv Prepr 2019. doi:10.1101/532291.

444 [30] Shirer WR, Ryali S, Rykhlevskaia E, Menon V, Greicius MD. Decoding subject-driven cognitive states
445 with whole-brain connectivity patterns. Cereb Cortex 2012;22:158–65.
446 doi:10.1093/cercor/bhr099.

447 [31] Blankertz B, Lemm S, Treder M, Haufe S, Müller K-R. Single-trial analysis and classification of ERP
448 components--a tutorial. Neuroimage 2011;56:814–25. doi:10.1016/j.neuroimage.2010.06.048.

449 [32] Ledoit O, Wolf M. A well-conditioned estimator for large-dimensional covariance matrices. J
450 Multivar Anal 2004;88:365–411. doi:10.1016/S0047-259X(03)00096-4.

451 [33] Lemm S, Blankertz B, Dickhaus T, Müller K-R. Introduction to machine learning for brain imaging.
452 Neuroimage 2011;56:387–99. doi:10.1016/j.neuroimage.2010.11.004.

453 [34] Fan L, Li H, Zhuo J, Zhang Y, Wang J, Chen L, et al. The Human Brainnetome Atlas: A New Brain Atlas
454 Based on Connectional Architecture. Cereb Cortex 2016;26:3508–26. doi:10.1093/cercor/bhw157.

455 [35] Krishnan A, Williams LJ, McIntosh AR, Abdi H. Partial Least Squares (PLS) methods for
456 neuroimaging: A tutorial and review. Neuroimage 2011;56:455–75.
457 doi:10.1016/j.neuroimage.2010.07.034.

458 [36] Dawson JF, Richter AW. Probing three-way interactions in moderated multiple regression:
459 Development and application of a slope difference test. J Appl Psychol 2006;91:917–26.
460 doi:10.1037/0021-9010.91.4.917.

461 [37] Samu D, Campbell KL, Tsvetanov KA, Shafto MA, Consortium C-C, Brayne C, et al. Preserved
462 cognitive functions with age are determined by domain-dependent shifts in network responsivity.
463 Nat Commun 2017;8:ncomms14743. doi:10.1038/ncomms14743.

464 [38] Contreras JA, Goñi J, Risacher SL, Amico E, Yoder K, Dzemidzic M, et al. Cognitive complaints in
465 older adults at risk for Alzheimer's disease are associated with altered resting-state networks.
466 Alzheimer's Dement Diagnosis, Assess Dis Monit 2017;6:40–9. doi:10.1016/J.DADM.2016.12.004.

467 [39] Cabeza R, Albert M, Belleville S, Craik FIM, Duarte A, Grady CL, et al. Maintenance, reserve and
468 compensation: the cognitive neuroscience of healthy ageing. Nat Rev Neurosci 2018;19:701–10.

469 doi:10.1038/s41583-018-0068-2.

470 [40] Hedden T, Van Dijk KRA, Becker JA, Mehta A, Sperling RA, Johnson KA, et al. Disruption of functional
471 connectivity in clinically normal older adults harboring amyloid burden. J Neurosci 2009;29:12686–
472 94. doi:10.1523/JNEUROSCI.3189-09.2009.

473 [41] Murley AG, Rowe JB. Neurotransmitter deficits from frontotemporal lobar degeneration. Brain
474 2018;141:1263–85. doi:10.1093/brain/awx327.

475 [42] Rittman T, Rubinov M, Vértes PE, Patel AX, Ginestet CE, Ghosh BCP, et al. Regional expression of
476 the MAPT gene is associated with loss of hubs in brain networks and cognitive impairment in
477 Parkinson disease and progressive supranuclear palsy. Neurobiol Aging 2016;48:153–60.
478 doi:10.1016/J.NEUROBIOLAGING.2016.09.001.

479 [43] Geerligs L, Tsvetanov KAKA. The use of resting state data in an integrative approach to studying
480 neurocognitive ageing – Commentary on Campbell and Schacter (2016). Lang Cogn Neurosci
481 2016;32. doi:http://dx.doi.org/10.1080/23273798.2016.1251600.

482 [44] Vemuri P, Lesnick TG, Przybelski SA, Knopman DS, Preboske GM, Kantarci K, et al. Vascular and
483 amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain
484 2015;138:761–71. doi:10.1093/brain/awu393.

485 [45] Rodrigue KM, Kennedy KM, Devous MD, Rieck JR, Hebrank AC, Diaz-Arrastia R, et al. β-Amyloid
486 burden in healthy aging: regional distribution and cognitive consequences. Neurology
487 2012;78:387–95. doi:10.1212/WNL.0b013e318245d295.

488 [46] Klöppel S, Gregory S, Scheller E, Minkova L, Razi A, Durr A, et al. Compensation in Preclinical
489 Huntington's Disease: Evidence From the Track-On HD Study. EBioMedicine 2015;2:1420–9.
490 doi:10.1016/j.ebiom.2015.08.002.

491 [47] Gregory S, Long JD, Klöppel S, Razi A, Scheller E, Minkova L, et al. Operationalizing compensation
492 over time in neurodegenerative disease. Brain 2017;140:1158–65. doi:10.1093/brain/awx022.

493 [48] Sullivan MD, Anderson JAE, Turner GR, Spreng RN. Intrinsic neurocognitive network connectivity
494 differences between normal aging and mild cognitive impairment are associated with cognitive
495 status and age. Neurobiol Aging 2019;73:219–28. doi:10.1016/J.NEUROBIOLAGING.2018.10.001.

496 [49] Blesa J, Trigo-Damas I, Dileone M, del Rey NL-G, Hernandez LF, Obeso JA. Compensatory
497 mechanisms in Parkinson's disease: Circuits adaptations and role in disease modification. Exp
498 Neurol 2017;298:148–61. doi:10.1016/J.EXPNEUROL.2017.10.002.

499 [50] Wen M-C, Heng HSE, Hsu J-L, Xu Z, Liew GM, Au WL, et al. Structural connectome alterations in
500 prodromal and de novo Parkinson's disease patients. Parkinsonism Relat Disord 2017;45:21–7.
501 doi:10.1016/j.parkreldis.2017.09.019.

502 [51] Stern Y. Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol 2012;11:1006–12.
503 doi:10.1016/S1474-4422(12)70191-6.

504 [52] Lattante S, Le Ber I, Galimberti D, Serpente M, Rivaud-Péchoux S, Camuzat A, et al. Defining the
505 association of TMEM106B variants among frontotemporal lobar degeneration patients with GRN
506 mutations and C9orf72 repeat expansions. Neurobiol Aging 2014;35:2658.e1-2658.e5.
507 doi:10.1016/J.NEUROBIOLAGING.2014.06.023.

508 [53] Koriath C, Kenny J, Adamson G, Druyeh R, Taylor W, Beck J, et al. Predictors for a dementia gene
509 mutation based on gene-panel next-generation sequencing of a large dementia referral series. Mol
510 Psychiatry 2018. doi:10.1038/s41380-018-0224-0.

511 [54] Sami S, Williams N, Hughes LE, Cope TE, Rittman T, Coyle-Gilchrist ITS, et al. Neurophysiological
512 signatures of Alzheimer's disease and frontotemporal lobar degeneration: pathology versus
513 phenotype. Brain 2018;141:2500–10. doi:10.1093/brain/awy180.

514 [55] Campbell KL, Shafto MA, Wright P, Tsvetanov KA, Geerligs L, Cusack R, et al. Idiosyncratic
515 responding during movie-watching predicted by age differences in attentional control. Neurobiol
516 Aging 2015;36:3045–55. doi:10.1016/j.neurobiolaging.2015.07.028.

517

518

519

520

521 # 6. Acknowledgements

522 Kamen A. Tsvetanov is supported by the British Academy (Postdoctoral Fellowship, PF160048).
523 James B Rowe is supported by the Wellcome Trust (103838) the Medical Research Council (SUAG/051
524 G101400) and the Cambridge NIHR Biomedical Research Centre. Raquel Sánchez-Valle is supported by the
525 Instituto de Salud Carlos III and the JPND network PreFrontAls (01ED1512/AC14/0013) and the Fundació
526 Marató de TV3 (20143810).

527

528

529 # 7. Tables

530 *Table 1. Demographics of participants included in the analysis, grouped by genetic status*
531 *as non-carriers (NC) and presymptomatic carriers (PSC). * denotes whether demographics vary*
532 *between NC and PSC groups.*

		Gene Carrier Group		Statistical tests*	
		NC	PSC	X^2 or F-test	*P*-value
N		134	121		
Age				2.68	0.103
	Mean / SD	49 / 14	46 / 11		
	Range [Min/Max]	19 / 86	20 / 70		
Gender, n (%)				0.01	0.908
	Men	53 (39.6)	47 (38.8)		
	Women	81 (60.4)	74 (61.2)		
Expected Years to Onset				0.23	0.631
	Mean / SD	-10 / 12	-11 / 11		
	Range [Min/Max]	-25 / 10	-25 / 10		
Education				0.05	0.826
	Mean / SD	14 / 3	14 / 3		
	Range [Min/Max]	5 / 24	5 / 22		
Mini-Mental State Examination				0.39	0.532
	Mean / SD	29 / 1	29 / 1		
	Range [Min/Max]	25 / 30	23 / 30		

533

8. Figures



$$LV_{Cognition} \sim \beta_0 + \beta_1 LV_{Brain} + \beta_2 Group + \beta_3 EYO + \cdots + \beta_7 LV_{Brain} \times Group \times EYO + \beta_{8:n} Cov_{1:n-7}$$

Figure 1. Schematic representation of data processing and analysis pipeline to test for brain-behaviour differences between presymptomatic carriers (PSC) and non-carriers (NC) as a function of expected years to onset (EYO) of symptoms, while controlling for covariates of no interest (Covs). Brain structural measures were based on the mean grey matter volume (GMV) in 246 nodes, as defined in the Brainnetome atlas [34]. *Brain functional measures were based on the functional connectivity between 15 nodes as part of four large-scale networks, which were defined in an independent cohort of 298 age-matched individuals part of the Cam-CAN dataset (Passamonti et al 2019 BioArxiv).*



Figure 2. Visualisation of spatial localisation of the nodes part of the four large-scale networks and their mean functional connectivity (circular plot) across all participants in this study. Nodes and networks were defined in an independent cohort of 298 age-matched individuals part of the Cam-CAN dataset (Passamonti et al 2019).The default mode network (DMN) contained five nodes: the ventral anterior cingulate cortex (vACC), dorsal and ventral posterior cingulate cortex (vPCC and dPCC), and right and left inferior parietal lobes (rIPL and lIPL). The salience network (SN) was defined using right and left anterior insular (rAI and lAI) and dorsal anterior cingulate cortex (dACC). The frontoparietal network (FPN) was defined using right and left anterior superior frontal gyrus (raSFG and laSFG), and right and left angular gyrus (rAG and lAG). The dorsal attention Network (DAN) was defined using right and left intraparietal sulcus (rIPS and lIPS).



Figure 3. Group differences between PSC and NC in grey matter volume (left panel) and functional connectivity between nodes within four large scale networks (right panel). Hot colour scheme indicates the strength of effect size of PSC showing higher GMV and FC than NC, while cold colour scheme indicates the opposite effect (i.e. NC > PSC).



Figure 4. PLS analysis of grey matter volume (GMV) and cognition indicating the spatial distribution of GMV loading values (a), where hot and cold colour schemes are used for the strength of positive and negative correlations with the profile of Cognitive LV (b). (c) The scatter plot on the left represents the relationship between subjects scores of GMV LV and Cognition LV for presymptomatic carriers (PSC) and non-carriers (NC). The scatter plots in the middle and right hand-side represent GMV-Cognition LV relationship as a function of expected years to onset (EYO, split in two groups, Near and Far, see text) in each gene group separately.



572

573 *Figure 5. PLS analysis of functional connectivity and cognition indicating the connectivity*
574 *pattern of loading values (a), where hot and cold colour schemes are used for the strength of*
575 *positive and negative correlations with the profile of Cognitive LV (b). (c) The scatter plot on the*
576 *left represents the relationship between subjects scores of Function LV and Cognition LV for*
577 *presymptomatic carriers (PSC) and non-carriers (NC). The scatter plots in the middle and right*
578 *hand-side represents Function-Cognition LV relationship as a function of expected years to onset*
579 *(EYO split in two groups, Near and Far, see text) in each gene group separately, which is also*
580 *represented using a bar chart in (d). * denotes significant test at p-value < 0.05.*

9. APPENDIX

List of other GENFI consortium members

Sónia Afonso - Instituto Ciencias Nucleares Aplicadas a Saude, Universidade de Coimbra, Coimbra, Portugal

Maria Rosario Almeida - Centre of Neurosciences and Cell Biology, Universidade de Coimbra, Coimbra, Portugal

Sarah Anderl-Straub – Department of Neurology, Ulm University, Ulm, GermanyChristin Andersson - Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden

Anna Antonell - Alzheimer's disease and other cognitive disorders unit, Neurology Department, Hospital Clinic, Institut d'Investigacions Biomèdiques, Barcelona, Spain

Silvana Archetti - Biotechnology Laboratory, Department of Diagnostics, Spedali Civili Hospital, Brescia, Italy

Andrea Arighi - Fondazione IRCSS Ca' Granda, Ospedale Maggiore Policlinico, Neurodegenerative Diseases Unit, Milan, Italy

Mircea Balasa - Alzheimer's disease and other cognitive disorders unit, Neurology Department, Hospital Clinic, Institut d'Investigacions Biomèdiques, Barcelona, Spain

Myriam Barandiaran - Neuroscience Area, Biodonostia Health Research Institute, Paseo Dr Begiristain sn, CP 20014, San Sebastian, Gipuzkoa, Spain

Nuria Bargalló - Radiology Department, Image Diagnosis Center, Hospital Clínic and Magnetic Resonance Image core facility, IDIBAPS, Barcelona, Spain

Robart Bartha - Department of Medical Biophysics, Robarts Research Institute, University of Western Ontario, London, Ontario, Canada

Benjamin Bender - Department of Diagnostic and Interventional Neuroradiology, University of Tuebingen, Tuebingen, Germany

Luisa Benussi - Istituto di Ricovero e Cura a Carattere Scientifico Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy

Valentina Bessi - Department of Neuroscience, Psychology, Drug Research, and Child Health, University of Florence, Florence, Italy

Giuliano Binetti - Istituto di Ricovero e Cura a Carattere Scientifico Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy

Sandra Black - LC Campbell Cognitive Neurology Research Unit, Sunnybrook Research Institute, Toronto, Canada

Martina Bocchetta – Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square London, UK

Sergi Borrego-Ecija - Alzheimer's disease and other cognitive disorders unit, Neurology Department, Hospital Clinic, Institut d'Investigacions Biomèdiques, Barcelona, Spain

Jose Bras – Dementia Research Institute, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK

Rose Bruffaerts - Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium

Paola Caroppo - Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta, Milan, Italy

David Cash – Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK

Miguel Castelo-Branco - Neurology Department, Centro Hospitalar e Universitário de Coimbra, Instituto de Ciências Nucleares Aplicadas à Saúde (ICNAS), Coimbra, Portugal

Rhian Convery – Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK

Thomas Cope – Department of Clinical Neuroscience, University of Cambridge, Cambridge, UK

Maura Cosseddu – Centre for Neurodegenerative Disorders, Neurology Unit, Spedali Civili Hospital, Brescia, Italy

María de Arriba - Neuroscience Area, Biodonostia Health Research Institute, Paseo Dr Begiristain sn, CP 20014, San Sebastian, Gipuzkoa, Spain

Giuseppe Di Fede - Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta, Milan, Italy

Zigor Díaz - CITA Alzheimer, San Sebastian, Spain

Katrina M Moore – Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK
Diana Duro - Faculty of Medicine, Universidade de Coimbra, Coimbra, Portugal
Chiara Fenoglio - University of Milan, Centro Dino Ferrari, Milan, Italy
Camilla Ferrari - Department of Neuroscience, Psychology, Drug Research, and Child Health, University of Florence, Florence, Italy
Carlos Ferreira - Instituto Ciências Nucleares Aplicadas à Saúde, Universidade de Coimbra, Coimbra, Portugal
Catarina B. Ferreira - Faculty of Medicine, University of Lisbon, Lisbon, Portugal
Toby Flanagan – Faculty of Biology, Medicine and Health, Division of Neuroscience and Experimental Psychology, University of Manchester, Manchester, UK
Nick Fox – Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK
Morris Freedman - Division of Neurology, Baycrest Centre for Geriatric Care, University of Toronto, Toronto, Canada
Giorgio Fumagalli - Fondazione IRCSS Ca' Granda, Ospedale Maggiore Policlinico, Neurodegenerative Diseases Unit, Milan, Italy; Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy
Alazne Gabilondo - Neuroscience Area, Biodonostia Health Research Institute, Paseo Dr Begiristain sn, CP 20014, San Sebastian, Gipuzkoa, Spain
Roberto Gasparotti - Neuroradiology Unit, University of Brescia, Brescia, Italy
Serge Gauthier - Department of Neurology and Neurosurgery, McGill University, Montreal, Québec, Canada
Stefano Gazzina - Centre for Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
Giorgio Giaccone - Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta, Milan, Italy
Ana Gorostidi - Neuroscience Area, Biodonostia Health Research Institute, Paseo Dr Begiristain sn, CP 20014, San Sebastian, Gipuzkoa, Spain
Caroline Greaves – Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square London, UK
Rita Guerreiro – Dementia Research Institute, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK
Carolin Heller – Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK
Tobias Hoegen - Department of Neurology, Ludwig-Maximilians-University of Munich, Munich, Germany
Begoña Indakoetxea - Cognitive Disorders Unit, Department of Neurology, Donostia University Hospital, Paseo Dr Begiristain sn, CP 20014, San Sebastian, Gipuzkoa, Spain
Vesna Jelic - Division of Clinical Geriatrics, Karolinska Institutet, Stockholm, Sweden
Lize Jiskoot - Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
Hans-Otto Karnath - Section of Neuropsychology, Department of Cognitive Neurology, Center for Neurology & Hertie-Institute for Clinical Brain Research, Tübingen, Germany
Ron Keren - University Health Network Memory Clinic, Toronto Western Hospital, Toronto, Canada
Maria João Leitão - Centre of Neurosciences and Cell Biology, Universidade de Coimbra, Coimbra, Portugal
Albert Lladó - Alzheimer's disease and other cognitive disorders unit, Neurology Department, Hospital Clinic, Institut d'Investigacions Biomèdiques, Barcelona, Spain
Gemma Lombardi - Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy
Sandra Loosli - Department of Neurology, Ludwig-Maximilians-University of Munich, Munich, Germany
Carolina Maruta - Lisbon Faculty of Medicine, Language Research Laboratory, Lisbon, Portugal
Simon Mead - MRC Prion Unit, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK
Lieke Meeter - Department of Neurology, Erasmus Medical Center, Rotterdam, Netherlands
Gabriel Miltenberger - Faculty of Medicine, University of Lisbon, Lisbon, Portugal
Rick van Minkelen - Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands
Sara Mitchell - LC Campbell Cognitive Neurology Research Unit, Sunnybrook Research Institute, Toronto, Canada

Benedetta Nacmias - Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy
Mollie Neason - Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK
Jennifer Nicholas – Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK
Linn Öijerstedt - Department of Geriatric Medicine, Karolinska Institutet, Stockholm, Sweden
Jaume Olives - Alzheimer's disease and other cognitive disorders unit, Neurology Department, Hospital Clinic, Institut d'Investigacions Biomèdiques, Barcelona, Spain
Alessandro Padovani - Centre for Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
Jessica Panman – Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
Janne Papma - Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
Irene Piaceri - Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence
Michela Pievani - Istituto di Ricovero e Cura a Carattere Scientifico Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
Yolande Pijnenburg - VUMC, Amsterdam, The Netherlands
Cristina Polito - Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", Nuclear Medicine Unit, University of Florence, Florence, Italy
Enrico Premi - Stroke Unit, Neurology Unit, Spedali Civili Hospital, Brescia, Italy
Sara Prioni - Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta, Milan, Italy
Catharina Prix - Department of Neurology, Ludwig-Maximilians-University Munich, Germany
Rosa Rademakers - Department of Neurosciences, Mayo Clinic, Jacksonville, Florida, USA
Veronica Redaelli - Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta, Milan, Italy
Tim Rittman – Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
Ekaterina Rogaeva - Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada
Pedro Rosa-Neto - Translational Neuroimaging Laboratory, McGill University Montreal, Québec, Canada
Giacomina Rossi - Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta, Milan, Italy
Martin Rossor – Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK
Beatriz Santiago - Neurology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
Elio Scarpini - University of Milan, Centro Dino Ferrari, Milan, Italy; Fondazione IRCSS Ca' Granda, Ospedale Maggiore Policlinico, Neurodegenerative Diseases Unit, Milan, Italy
Sonja Schönecker - Neurologische Klinik, Ludwig-Maximilians-Universität München, Munich, Germany
Elisa Semler – Department of Neurology, Ulm University, Ulm, Germany
Rachelle Shafei – Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK
Christen Shoesmith - Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario, Canada
Miguel Tábuas-Pereira - Centre of Neurosciences and Cell Biology, Universidade de Coimbra, Coimbra, Portugal
Mikel Tainta - Neuroscience Area, Biodonostia Health Research Institute, Paseo Dr Begiristain sn, CP 20014, San Sebastian, Gipuzkoa, Spain
Ricardo Taipa - Neuropathology Unit and Department of Neurology, Centro Hospitalar do Porto - Hospital de Santo António, Oporto, Portugal
David Tang-Wai - University Health Network Memory Clinic, Toronto Western Hospital, Toronto, Canada
David L Thomas - Neuroradiological Academic Unit, UCL Institute of Neurology, London, UK
Hakan Thonberg - Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, Stockholm, Sweden
Carolyn Timberlake - University of Cambridge, Cambridge, UK

Pietro Tiraboschi - Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta, Milano, Italy
Philip Vandamme - Neurology Service, University Hospitals Leuven, Belgium; Laboratory for Neurobiology, VIB-KU Leuven Centre for Brain Research, Leuven, Belgium
Mathieu Vandenbulcke - Geriatric Psychiatry Service, University Hospitals Leuven, Belgium; Neuropsychiatry, Department of Neurosciences, KU Leuven, Leuven, Belgium
Michele Veldsman - University of Oxford, UK
Ana Verdelho - Department of Neurosciences, Santa Maria Hospital, University of Lisbon, Portugal
Jorge Villanua - OSATEK Unidad de Donostia, San Sebastian, Gipuzkoa, Spain
Jason Warren – Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK
Carlo Wilke - Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany
Ione Woollacott – Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK
Elisabeth Wlasich - Neurologische Klinik, Ludwig-Maximilians-Universität München, Munich, Germany
Henrik Zetterberg - Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK
Miren Zulaica - Neuroscience Area, Biodonostia Health Research Institute, Paseo Dr Begiristain sn, CP 20014, San Sebastian, Gipuzkoa, Spain.